喘在五个欧洲国家的患病率和负担:一项回顾性横截面研究
Asif H Khan1, Imène Gouia2, Juby Jacob-Nara3
1Sanofi, Morristown, New Jersey, USA asif.khan@sanofi.com.
BMJ open
|May 23, 2025
概括
喘影响了五个欧洲国家的6.7%的成年人,严重影响了生活质量和医疗保健使用. 这项研究强调了喘的持续负担和需要更好的干预措施.
科学领域:
- 公共卫生 公共卫生
- 流行病学 流行病学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 喘是一个重大的全球健康问题,其流行率和影响在不同地区各不相同.
- 了解特定欧洲人口中的喘负担对于有针对性的公共卫生战略至关重要.
研究的目的:
- 量化五个欧洲国家 (法国,德国,意大利,西班牙和英国) 的喘患病率和评估整体喘负担.
- 为了在不同喘严重程度群体和非喘个体之间比较与健康相关的生活质量 (HRQoL),工作生产力,活动障碍和医疗资源利用率 (HCRU).
主要方法:
- 一项回顾性横截面研究,利用了2018年国家健康和健康调查的数据.
- 在成年患者 (≥18岁) 中进行了基于互联网的调查,这些患者患有医生诊断的喘和最近的喘症状.
- 包括HRQoL,生产力损失和HCRU在内的结果在喘严重程度 (轻度,中度,严重) 之间进行了分析,并与非喘对照进行了比较.
主要成果:
- 五个欧洲国家的整体喘患病率为6.7%,英国的患病率最高,为10.4%.
- 与没有喘的人相比,喘患者报告的HRQoL显著降低,工作和活动受损程度更高,医疗保健利用率增加 (急诊室访问,提供者访问,住院治疗) (p<0.001).
- 随着喘严重程度的增加 (中度/重度与轻度喘) 观察到结果恶化的持续趋势.
结论:
- 喘在西欧仍然是一个重要的公共卫生问题,其特点是患病率高,疾病负担很大.
- 这些发现强调,迫切需要开发和实施有效的喘管理干预措施,以改善患者的治疗结果.
相关概念视频
Asthma-I: Introduction
2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
Asthma-III: Symptoms and Complications
2.7K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.7K
Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Asthma: Pathogenesis and Management
628
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
628
Antiasthma Drugs: Leukotriene Modifiers
515
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
515


